A Randomized OPen-label Active controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing ...
In order to achieve 200 per-protocol subjects, approximately 250 eligible subjects, age 18 years or older, with a history of ...
Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors
Since 2006, there has been a 50% increase in the number of adults added to the heart transplant waitlist in ...
Electrogram Guided Myocardial Advanced Phenotyping (EMAP) Study for patients recently diagnosed with cardiomyopathy
This study is enrolling newly diagnosed heart failure (within 6 months from diagnosis) patients with no known cause for their ...
LIFE Study: Entresto TM in Advanced Heart Failure
This study aims to understand the benefits/risks of Entresto in NYHA III-IV patients.
Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis
The study is evaluating the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) in comparison with ...
Attain StarFix Model 4195 LV Lead Extraction Study
The purpose of this study is to characterize the removability of the Attain StarFix®Model 4195 Left Ventricular (LV) Lead ...
Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure
Randomized (flip of the coin 50/50) study of heart failure (HF) patients with moderate aortic valve stenosis (narrowing) will ...
DCPMS: Dialated Cardiomyopathy Precision Medicine Study
This study aims to understand the effects of potential familial/genetic links in an otherwise unclear origin of a patient ...
Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
The purpose of this study is to compare the effect of the investigational drug, mavacamten, (MYK-461), to a placebo (an ...
“The Shift Worker’s Microbiome”
We are looking for healthy males, age 40-59 years old, non-smoking un-medicated who work the "shift-work" schedule (>3 shifts per ...
Lavenia M Banas, Rn
Showing - of trials